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Zhen-Yu Ding1,2, Hong Zhang3, Gunnar Adell4, Birgit Olsson1 and Xiao-Feng Sun1*Abstract
Background: This study was aimed to investigate the expression significance of Livin in relation to radiotherapy
(RT), clinicopathological and biological factors of rectal cancer patients.
Methods: This study included 144 primary rectal cancer patients who participated in a Swedish clinical trial of
preoperative radiotherapy. Tissue microarray samples from the excised primary rectal cancers, normal mucosa and
lymph node metastases were immunostained with Livin antibody. The proliferation of colon cancer cell lines SW620
and RKO was assayed after Livin knock-down.
Results: The expression of Livin was significantly increased from adjacent (P = 0.051) or distant (P = 0.028) normal
mucosa to primary tumors. 15.4% (2/13) and 39.7% (52/131) patients with Livin-negative and positive tumors died
at 180 months after surgery, and the difference tended to be statistically significant (P = 0.091). In multivariate
analyses, the difference achieved statistical significance, independent of TNM stage, local and distant recurrence, grade
of differentiation, gender, and age (odds ratio = 5.09, 95% CI: 1.01-25.64, P = 0.048). The in vitro study indicated colon
cancer cells with Livin knock-down exhibited decreased proliferation compared with controls after RT.
Conclusions: The expression of Livin was was independently related to survival in rectal cancer patients, suggesting
Livin as a useful prognostic factor for rectal cancer patients.
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Colorectal cancer (CRC) is one of the leading causes of
cancer death in Western countries [1,2]. Surgery remains
the curative modality for the CRC, and preoperative
radiotherapy (RT) has shown a survival advantage com-
pared with surgery alone. However, the value of pre-
operative RT still remains controversial [3-5]. There is
an urgent need to search for predictive indicators to
identify patients who can be benefited from preoperative
radiotherapy.
Many molecules that participate the biological process
of proliferation and apoptosis have been proposed as po-
tential indicators for RT. We have previously reported
that Survivin from the Inhibitor of Apoptosis (IAP)* Correspondence: xiao-feng.sun@liu.se
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[6]. Till now, another IAP family member Livin has been
identified [7-9]. It is expressed in variant tumors such as
melanoma, leukemia, bladder cancer, breast cancer, cer-
vical cancer, nasopharyngeal cancer and lung cancer
[10-13]. Two isoforms (designated α- and β-) were de-
scribed due to alternative splicing, which are almost
identical except for a 54 bp truncation in exon 6 [14].
Both isoforms block apoptosis induced by TNF-α and
anti-CD95 antibody.
However, little is known on the Livin expression in CRC
except for preliminary in vitro reports [15]. Neither is it
known about the relationship between Livin expression
and radiotherapy. In this study, we investigated the rela-
tionships of Livin expression to radiotherapy and to clini-
copathologic or biologic variables in CRC patients who
participated in a clinical trial of preoperative radiotherapy.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of patients and tumors





Male 44 (57) 42 (63)
Female 33 (43) 25 (37)
Age (years)
≤70 45 (58) 45 (67)
>70 32 (42) 22 (33)
TNM stage
I 19 (25) 20 (30)
II 19 (25) 22 (33)
III 35 (45) 19 (28)
IV 4 (5) 6 (9)
Differentiation
Good 60 (78) 49 (73)
Poor 17 (22) 18 (27)
Number of malignancies
Single 65 (84) 55 (82)
Multiple 10 (13) 12 (18)
Unknown 2 (3) 0
Surgical type
Rectal amputation 42 (55) 24 (36)
Anterior resection 35 (45) 43 (64)
Resection margin
Tumor free 73 (95) 63 (94)
Tumor 4 (5) 4 (6)
Distance to anal verge
(cm)
Mean 7.4 8.6
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Patients
The current study got approval from the ethics commit-
tee of Linkoping University and was in compliance with
the Helsinki Declaration. The present study included
144 rectal cancer patients from the Southeast Swedish
Health Care region who participated in the Swedish Rec-
tal Cancer Trial between 1987 and 1990 [3]. Of the 144
patients, 77 underwent tumor resection alone and 67
underwent preoperative RT and tumor resection. None
of the patients had received chemotherapy before sur-
gery. Besides the tumor specimens, matched normal mu-
cosa adjacent to the tumor tissue were collected from 71
cases, distant (4-35 cm from the primary tumor) normal
mucosa were collected from 110 cases, and metastases
in the regional lymph nodes were collected from 47
cases. The mean patient age was 66 years (range, 36-
85 years). The median follow-up was 85 months. RT was
given to 25 Gy in five fractions during a median of 8.5
Days (range, 6-18 days) [3]. Surgery was then performed
in a median of 3.4 days (0-11 days) after RT. The mean
tumor distance to the anal verge was 7.4 cm in the surgi-
cal group and 8.6 cm in the surgery plus RT group (P =
0.10). Other patient and tumor characteristics were pre-
sented in Table 1. No statistically significant differences
were found between the two groups.
Immunohistochemical (IHC) assay
Representative paraffin-embedded tissue blocks were se-
lected for the tissue microarray. Three morphologically
representative regions were chosen in each block and
three cyclindrical core core tissue specimens (0.6 mm in
diameter) were taken from these areas, inserted in an-
other paraffin block. Sections from the second block
were cut into 5 μm chips using a microtome, mounted
on microscopic slides. The tissue microarrays were con-
structed using a manual arrayer (Beecher Inc., WI).
IHC for Livin expression was done on 5-μM tissue
microarray sections from paraffin-embedded surgical spec-
imens. The sections were baked in an oven at 60°C for
over 6 hrs and then deparaffinized with xylene and rehy-
drated with a series of decreasing concentrations of etha-
nol. To demask antigen epitopes, the sections were soaked
in DIVA solution (Biocare Medical, CA) in a high pressure
cooker at 125°C for 30 sec after which the sections were
cooled to 90°C for 10 sec and then kept in room tem-
perature for 30 min followed by washing in phosphate
buffered solution (PBS, pH 7.4). To inhibit endogenous
peroxidase activity, the sections were incubated with 3%
H2O2-methanol for 20 min. After blocking with power
block solution (Spring Bioscience, CA) for 10 min, the sec-
tions were incubated with goat anti-Livin antibody (RnD,
MN) at a concentration of 2.5 μg/ml at 4°C overnight. En-
Vision anti-goat Polymeric conjugate (Dako, Carpinteria,CA) was subsequently applied for 30 min. The slides were
washed in PBS and the peroxidase reaction was performed
using 3,3’-diaminobenzidin (Sigma Chemical, St. Louis,
MO) and 3% H2O2. Finally, hematoxylin was used for
counterstaining. Sections known to show positive staining
for Livin were included for each turn, receiving either the
primary antibody or control isotype Ig, as positive or nega-
tive controls, whereas there was no staining in the negative
controls.
Measurement of the Livin expression by IHC
The IHC results of the Livin in tissue specimens were the
mean of scores by two independent authors (Z.-Y. D., and
H. Z., who is a pathologist) in a blinded fashion without
knowledge of the clinicopathological or biological infor-
mation. Each investigator estimated the proportion of cells
stained and the intensity of staining in the whole section.
The intensity in epithelial cells or tumor cells was scored
as 0 (negative staining), 1 (weak staining exhibited as light
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and 3 (strong staining exhibited as brown). If there was a
discrepancy in individual scores, then both investigators
re-evaluated the slides together to reach a consensus be-
fore combining the individual scores. To avoid an artificial
effect, the cells on the margins of the sections and in areas
with poor morphology were not counted.Evaluation of proliferation, P53, mammary tumor 8 kDa
(MAT8), ataxia telangiectasia mutated (ATM), apoptosis,
and necrosis
Proliferation in the cancer cells was measured using IHC
for Ki-67 as an indicator (n = 115). Low and high prolifera-
tion were defined in sections where <32% or ≥32% of can-
cer cells expressed Ki-67 [16]. The data for P53 (n = 139),
MAT8 (n = 124) and ATM (n = 66) of primary rectal can-
cers determined by IHC were taken from previous studies
performed with the same cases used in the present study at
out laboratory [17-19]. Apoptosis was detected by the ter-
minal deoxynucleotidy transferase-mediated dUTP-biotin
nick end labeling (TUNEL) assay [20].Cell culture
Human colon cancer cell lines RKO and SW620 were pur-
chased from the American Type Culture Collection. Cells
were maintained in Minimal Essential Medium (Sigma-
Aldrich) supplemented with 10% FBS (GIBCO, Invitrogen,
Carlsbad, USA), 1.5 mM L-glutamine (GIBCO) and 1X
PEST (GIBCO) at 37°C in a 5% CO2 incubator. Myco-
plasma contamination was excluded from the cells by
using a commercially available PCR kit (PromoKine,
Heidelberg, Germany). The endogenous Livin was knock-
down with ON-TARGETplusR SMARTpool siRNA against
Livin (L-004391-00-5551, Thermo Fisher) by using
DharmaFect 2 transfection reagent (Dharmacon) accord-
ing to the manufacturer’ instructions. The transfection
mixture consisted of antibiotic-free culture medium and
100 nM siRNA. The Dharmacon Non-Targeting scramble
siRNA was used as a negative control.Cell proliferation assay
The effect of radiotherapy on the proliferation of colon
cancer cells was quantified by WST-1 assay (Roche) ac-
cording to the manufacture’s instructions. Briefly, cells
were seeded in 96-well tissue culture plate, in 100 μl cul-
ture medium. 10 μl of WST-1 assay solution was added
to each well and the cells were further incubated at 37°C
for 2-3 hrs. The absorbance was measured at a wave-
length of 450 nm on a VersaMax microplate reader (Mo-
lecular Devices, Sunnyvale, CA). Untreated cells served
as the indicator of 100% cell viability.Statistical analysis
All the statistical analyses were performed by using the
SPSS software 19.0 (IBM software). The McNemar and
Chi-Square methods were used to test the statistical sig-
nificance of the differences in the Livin expression be-
tween different tissue specimens and the association of
Livin with the clinicopathological features, Ki-67, P53,
MAT8 and ATM. Cox’s proportional hazard model used
to estimate the relationship between Livin expression
and survival, including both univariate and multivariate
analyses. Survival curves were computed according to
the Kaplan-Meier method. Tests were two-sided, and
P < 0.05 was considered statistically significant.
Results
Livin expression in normal mucosa, primary tumor and
lymph node metastasis
By immunostaining, Livin expression was predominantly
detected in the cytoplasm of epithelial cells of normal mu-
cosa, and tumor cells of primary cancers and lymph node
metastases, with little staining in the nuclei (Figure 1A and
Additional file 1). For further analysis of the study, only the
staining of the cytoplasmic Livin was measured and pre-
sented. Of the 144 primary tumors examined, Livin expres-
sion was negative in 13 cases (9%), weak in 32 cases (22%),
moderate in 72 cases (50%), and strong in 27 cases (19%).
The frequency of high expression (moderate or strong
staining) of Livin was significantly increased from distant
normal mucosa (17%, 19/110; P = 0.028) or adjacent nor-
mal mucosa (17%, 12/71; P = 0.051) to primary tumors
(69%, 99/144), while the expression was not different from
primary tumors to lymph node metastases (40%, 19/47;
P = 0.357). There was no significant difference between dis-
tant and adjacent normal mucosa (P = 0.367, Figure 1B).
Effect of preoperative RT on Livin expression in the
normal mucosa, primary cancer and lymph node
metastasis
Compared with the cases without preoperative RT, the
frequency of Livin-positive expression in primary can-
cers with preoperative RT was decreased from 97% to
83% (P = 0.004), while in the distant normal mucosa, the
frequency of Livin-positive expression was increased
(71% VS 89%, P = 0.021). However, Livin-positive cases
in adjacent normal mucosa were not significantly influ-
enced by RT (75% VS 76%, P = 0.931). The frequency of
Livin-positive cases in the lymph node metastases was
unchanged in cases receiving preoperative RT (86% VS
90%, P =0.986).
Livin expression in relation to clinicopathological and
biological factors
In primary cancers, the expression of Livin was associated
with lower frequency of stage I and higher frequency of
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ferentiation of cancers (P = 0.033, Figure 2A). Patients with
Livin-positive or negative tumors had similar local (P =
0.647) and distant (P = 0.280) recurrence. The expression
of Livin was not related to gender, or age (P > 0.05). 15.4%
(2/13) and 39.7% (52/131) patients with Livin-negative or
positive tumors died at 180 months after surgery, and the
difference tended to be statistically significant (P = 0.091,
Figure 2B). In multivariate analyses, the difference achieved
statistical significance, independent of TNM stage, local
and distant recurrence, grade of differentiation, gender,
and age (P =0.048, Table 2).
In a subgroup analysis of the patients with preopera-
tive RT, a statistically significant difference was observed
between patients with Livin-positive or negative tumors
(P = 0.047). We did not find any relationship of Livin ex-
pression to TNM stage, grade of differentiation, gender,
or age in this subgroup (P >0.05). Due to a few cases
with Livin-negative tumors in the subgroup of the pa-
tients without preoperative RT, we did not perform stat-
istical analysis in the subgroup.
In the entire group, the frequency of expression of
Livin was related to the expression of Ki-67 (P =0.027),
p53 (P =0.012), MAT8 (P =0.020) and inversely related
to ATM (P =0.007).
In the patients without preoperative RT, high expres-
sion of Livin was still related to MAT8 (P =0.032) and
p53 (P =0.048), and inversely related to ATM (P =0.037,Figure 1 Livin expression in tumors and mucosa. Livin expression in no
The percentage of Livin high expresssion differes significantly between primFigure 3). In the patients with preoperative RT, no trend
was observed toward any of the relationship (P >0.05).
In the current study, the median overall survival was
similar between patients with (129 months) or without
(114 months) preoperative RT (P = 0.252).
Knock-down of Livin inhibited the proliferation of colon
cancer cells after irradiation
The endogenous Livin in SW620 and RKO colon cancer
cells was knocked-down by siRNA. The non-targeting
scramble siRNA was used as controls. The proliferation
of cancer cells after irradiation was monitored continu-
ously by WST-1 method. The colon cancer cells with
Livin knock-down exhibited significant decrease in pro-
liferation at each time point, compared scramble siRNA
treated controls (P <0.05, Figure 4).
Discussion
This is the first study of Livin expression in rectal cancer
patients who participated in a trial of preoperative RT.
Livin expression was described in colon cancer cell lines
at the protein or mRNA level [15,21-23], however few
reported the expression of Livin in rectal cancer tissues.
Yagihashi et al reported the detection of anti-Livin auto-
antibody in gastrointestinal patients, but this study failed
to confirm the Livin expression in tumor tissues either
[24]. In the present study, we found the extensive ex-
pression (91%) of Livin in CRC tissue specimens. Wermal mucosa, primary cancer, and lymph node metastases (A).
ary cancer and adjacent or distant normal mucosa (B).
Figure 2 Livin expression in relation to clinicopathological factors. Significant difference in Livin expression between early to advanced
stage or good to poor differentiation (A). Livin expression in relation to survival in entire group and subgroup with or without radiotherapy (B).
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cell lines [25]. The prevalent expression of Livin in CRC
tissues and cells suggested it plays a prominent role for
the progression of CRC.
Controversies remained on the prognostic value of Livin
in different tumor types. Livin over-expression together
with C-myc amplification in patients with neuroblastoma
predicated a poor prognosis [26]. In patients with bladder
cancer, increased Livin expression in tumors was associatedwith shorter duration of relapse-free survival [11]. Livin ex-
pression was also parallel with a decreased overall survival
in osteosarcoma patients [27]. Although most studies sup-
ported the negative impact of Livin on survival, mild influ-
ence or even favored prognosis was also reported. One
paper implicated the Livin expression was a favorable prog-
nostic factor in childhood acute lymphoblastic leukemia
[12]. However, the authors did not provide explanations for
the counter-instinctive results. In summary, it would be
Table 2 multivariate analysis of Livin in tumors in relation to survival
Factor Patients (n) Cancer death rate ratio (95% confidence interval ) p value
Livin expression 0.048
Negative 13 1.0
Positive 131 5.09 (1.01-25.64)
Gender 0.917
Male 86 1.0
Female 58 0.97 (0.52-1.79)
Age (years) 0.779
≤70 90 1.0
>70 54 1.08 (0.62-1.90)
Tumor stage <0.001
I + II + III 134 1.0
IV 10 5.40 (2.13-13.69)
Differentiation 0.881
Poor 138 1.0
Good 6 1.10 (0.31-3.99)
Local recurrence <0.001
No 121 1.0
Yes 23 3.31 (1.78-6.17)
Distant recurrence <0.001
No 85 1.0
Yes 59 12.48 (5.60-27.75)
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tissue and tumor specific. In the current study, we found
that Livin expression was an independent prognostic factor
for CRC patients after adjustment for TNM stage, local and
distant recurrence, grade of differentiation, gender, and age.
Our results provide new evidence in support of the import-
ant roles played by Livin in variant cancers.
In the present study, we individually examined the re-
lationship between Livin expression and survival in the
patients with or without preoperative RT. Our results
showed Livin expression in both the entire group andFigure 3 Livin expression in relation to other factors. The expression o
related to ATM in both the entire group and non-RT subgroup patients.the subgroup of patients receiving preoperative RT was
statistically related to poor prognosis. In the subgroup of
patients without preoperative RT, the expression of Livin
seemed to be related to the shorter overall survival. The
survival rate in patients with Livin-negative cancers was
100% (2/2) at 200 months after surgery. These evidence
supported the notion that Livin was related to survival
in CRC patients regardless of receiving preoperative RT
or surgery alone.
Few studies reported the differential expression of Livin
between primary cancers and adjacent normal mucosa. Inf Livin was related to the expression of Ki-67, p53, MAT8 and inversely
Figure 4 Knock-down of Livin makes cells more vulnerable to RT.
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69% of primay cancers and 40% of lymph node metasta-
ses, but only 17% of adjacent normal mucosa and 17%
of distant normal mucosa. The frequency of high ex-
pression of Livin was much higher in malignant tissues
than in normal mucosa. Studies performed in cancer
cells lines implicated the expression of Livin was under
the regulation of Catenin/TCF or mTOR pathways [28,29]
which were considered hallmark signaling changes in can-
cers [30]. These studies together with our results indicated
the Livin deregulation may contribute to the malignant
manifestation in cancers and may serve as a potential
therapeutic targets [31].
We analyzed the influence of preoperative RT on the
Livin expression, and observed a decrease of Livin expres-
sion in primary cancers in patients receiving preoperative
RT. Cancers have deregulated apoptotic pathway to pro-
tect them against harmful stimuli including radiation [30].
Anti-cancer treatment would overcome these molecular
hurdles to be effective [32]. In this way we believe Livin
was down-regulated by the preoperative RT in primary
cancers. The adjacent normal mucosa was suggested a
place of intermediate biologic change and had a similar
tendency with the primary cancers. However, Livin in the
distant mucosa might be up-regulated to protect the cells
from apoptosis by RT.
The underlying mechanism of Livin expression in as-
sociation with poor prognosis was probably attributed to
the negative regulation of apoptosis in response to RT.
Livin was proposed to block apoptosis by inhibiting the
activity of caspases [7,8] or involved in the TAK1/JNK1
pathway [33]. In the present study, we did not prove the
relationship between Livin expression and apoptosis in
the rectal cancer tissues. Similarly, our previous study
on Survivin did not prove the relationship to the apop-
tosis rate either [6]. One of the reasons may be due to
the “surgery-related apoptosis” which might influence
our results concerning apoptosis in relation to Livinexpression. We further analyzed the relationship of Livin
with Ki-67, P53, MAT8, and ATM. Ki-67 is a proven in-
dicator of cell proliferation [16]. P53 detected in IHC is
a mutated protein with oncogene properties [17]. MAT8
also named FXYD-3, is a chloride channel or chloride
channel regulator and acts as a prognostic factor for
cancers [18]. Livin expression was inversely related to
ATM which is a serine/threonine protein kinase in the
DNA damage repair pathway [34]. Our findings sug-
gested Livin might be involved in variant pathways in
the cell malignant phenotypes.
It should be noted that debate remained as to whether
apoptosis contributed to radiotherapy [35]. It was pro-
posed that apoptosis contributed to the short-term cyto-
cidal effects of radiotherapy, but not to the long-term
clone formation. In our study, we found the expression
of Livin was related to the prognosis in patients. We
wouldn’t be able to find the association between Livin
expression and apoptosis in this cohort of patients.
These results were in good agreement to the proposal
mentioned above. Therefore, the mechanistic explan-
ation for the current observations couldn’t be simply at-
tributed to apoptosis. Livin might be involved in other
phenotypes too. In support of this, a paper described its
regulation in cell cycle was published [36].
Our in vitro study showed decreased proliferation of
SW620 and RKO colon cancer cells after radiation when
the endogenous Livin was knocked down by RNAi. Con-
sistent with our findings, recent studies provided evidence
to support the role of Livin for treatment resistance.
Crnkovic-Mertens et al reported silencing Livin expression
strongly increased the apoptotic rate in response to differ-
ent stimuli [37,38]. Besides, Wang et al showed silencing
Livin inhibited the proliferation of tumor cells [22]. The
inhibition of proliferation was probably related to cell
cycle regulation [36]. Our previous results also showed
knock-down of Livin rendered the colon cancer cells
more sensitive to chemotherapy agent cisplatin [25]. The
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with the immunostaining results, where Livin was found
to be related to poor prognosis.
Of notice, the patients in our study were from a previous
randomized trial [3]. Although they were well-balanced
between groups (Table 1), the sample size was restricted
to the available banked tissue samples. The limited num-
ber of patients prevented any conclusive results. Addition-
ally, although our multivariate analysis might be helpful,
the problem of the heterogeneity in patients (stage I-IV)
could not be completely solved. All these limitations indi-
cated the results should be interpreted cautiously.
In summary, our study showed increased Livin expres-
sion in primary rectal cancers was related to the more ad-
vanced stage of cancer. Livin expression was independently
related to survival in rectal cancer patients who partici-
pated in a trial of preoperative RT, and it was associated
with survival in subgroup of patients receiving preoperative
RT too. Livin expression tended to be down regulated by
RT. Taken together, our data implicated Livin was a useful
prognostic factor for rectal cancer patients and possibly
served as a potential therapeutic target.
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